Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastics; anthraquinone derivatives | 1821 | 65271-80-9 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 7.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.78 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 7.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.25 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 53 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 23, 1987 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 304.10 | 26.17 | 165 | 5211 | 97502 | 50502246 |
Acute myeloid leukaemia | 207.91 | 26.17 | 73 | 5303 | 15001 | 50584747 |
Myelodysplastic syndrome | 159.10 | 26.17 | 60 | 5316 | 15072 | 50584676 |
Pancytopenia | 127.51 | 26.17 | 90 | 5286 | 83940 | 50515808 |
Second primary malignancy | 116.78 | 26.17 | 39 | 5337 | 6875 | 50592873 |
Sepsis | 112.54 | 26.17 | 101 | 5275 | 132824 | 50466924 |
Acute promyelocytic leukaemia | 103.66 | 26.17 | 23 | 5353 | 861 | 50598887 |
Neutropenia | 103.29 | 26.17 | 101 | 5275 | 147864 | 50451884 |
Thrombocytopenia | 83.20 | 26.17 | 84 | 5292 | 127589 | 50472159 |
Leukaemia recurrent | 80.40 | 26.17 | 20 | 5356 | 1234 | 50598514 |
Haemophagocytic lymphohistiocytosis | 75.63 | 26.17 | 30 | 5346 | 8603 | 50591145 |
Progressive multifocal leukoencephalopathy | 70.66 | 26.17 | 31 | 5345 | 11426 | 50588322 |
Bone marrow failure | 70.19 | 26.17 | 41 | 5335 | 27583 | 50572165 |
Acute myeloid leukaemia recurrent | 68.64 | 26.17 | 18 | 5358 | 1372 | 50598376 |
Bronchopulmonary aspergillosis | 65.17 | 26.17 | 26 | 5350 | 7566 | 50592182 |
Febrile bone marrow aplasia | 59.03 | 26.17 | 23 | 5353 | 6288 | 50593460 |
Chronic hepatitis | 56.89 | 26.17 | 14 | 5362 | 826 | 50598922 |
Congestive cardiomyopathy | 51.22 | 26.17 | 20 | 5356 | 5498 | 50594250 |
Lower respiratory tract infection fungal | 47.70 | 26.17 | 10 | 5366 | 285 | 50599463 |
Product use in unapproved indication | 47.58 | 26.17 | 60 | 5316 | 115759 | 50483989 |
Mucormycosis | 45.89 | 26.17 | 15 | 5361 | 2468 | 50597280 |
Cardiac failure | 43.99 | 26.17 | 47 | 5329 | 75993 | 50523755 |
Haematotoxicity | 41.16 | 26.17 | 19 | 5357 | 7876 | 50591872 |
Acute lymphocytic leukaemia recurrent | 40.87 | 26.17 | 13 | 5363 | 1962 | 50597786 |
Streptococcal bacteraemia | 40.37 | 26.17 | 12 | 5364 | 1446 | 50598302 |
Abdominal wall wound | 40.10 | 26.17 | 7 | 5369 | 72 | 50599676 |
Chloroma | 39.05 | 26.17 | 8 | 5368 | 203 | 50599545 |
Graft versus host disease | 39.04 | 26.17 | 17 | 5359 | 6149 | 50593599 |
Bone marrow infiltration | 37.85 | 26.17 | 9 | 5367 | 459 | 50599289 |
Hypogammaglobulinaemia | 37.02 | 26.17 | 16 | 5360 | 5683 | 50594065 |
Myeloblast percentage decreased | 36.56 | 26.17 | 6 | 5370 | 41 | 50599707 |
Refractory cytopenia with multilineage dysplasia | 35.71 | 26.17 | 7 | 5369 | 141 | 50599607 |
Multiple organ dysfunction syndrome | 34.32 | 26.17 | 34 | 5342 | 50303 | 50549445 |
Aspergillus infection | 34.26 | 26.17 | 16 | 5360 | 6805 | 50592943 |
Hepatitis E | 33.53 | 26.17 | 10 | 5366 | 1219 | 50598529 |
Arthralgia | 30.61 | 26.17 | 5 | 5371 | 438697 | 50161051 |
Stem cell transplant | 30.52 | 26.17 | 10 | 5366 | 1658 | 50598090 |
Stenotrophomonas infection | 30.51 | 26.17 | 10 | 5366 | 1659 | 50598089 |
Bacterial sepsis | 29.71 | 26.17 | 12 | 5364 | 3600 | 50596148 |
Respiratory failure | 29.40 | 26.17 | 42 | 5334 | 91139 | 50508609 |
Clostridium bacteraemia | 28.16 | 26.17 | 6 | 5370 | 185 | 50599563 |
Colitis | 28.08 | 26.17 | 27 | 5349 | 38502 | 50561246 |
Chronic myeloid leukaemia | 28.00 | 26.17 | 10 | 5366 | 2146 | 50597602 |
Venoocclusive liver disease | 27.80 | 26.17 | 12 | 5364 | 4249 | 50595499 |
Leukopenia | 27.72 | 26.17 | 35 | 5341 | 67493 | 50532255 |
Differentiation syndrome | 27.23 | 26.17 | 8 | 5368 | 925 | 50598823 |
Cardiomyopathy | 26.63 | 26.17 | 18 | 5358 | 15568 | 50584180 |
Aplastic anaemia | 26.59 | 26.17 | 14 | 5362 | 7689 | 50592059 |
Streptococcal sepsis | 26.33 | 26.17 | 9 | 5367 | 1698 | 50598050 |
Neoplasm progression | 26.25 | 26.17 | 23 | 5353 | 29134 | 50570614 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 356.91 | 22.00 | 253 | 6468 | 111987 | 29455819 |
Myelodysplastic syndrome | 166.27 | 22.00 | 81 | 6640 | 17713 | 29550093 |
Acute myeloid leukaemia | 141.85 | 22.00 | 71 | 6650 | 16442 | 29551364 |
Neutropenia | 108.39 | 22.00 | 141 | 6580 | 131570 | 29436236 |
Septic shock | 100.15 | 22.00 | 95 | 6626 | 62465 | 29505341 |
Bone marrow failure | 82.28 | 22.00 | 60 | 6661 | 27389 | 29540417 |
Bronchopulmonary aspergillosis | 80.05 | 22.00 | 44 | 6677 | 12300 | 29555506 |
Mucormycosis | 75.06 | 22.00 | 32 | 6689 | 5126 | 29562680 |
Fungal infection | 73.17 | 22.00 | 43 | 6678 | 13642 | 29554164 |
Second primary malignancy | 60.99 | 22.00 | 30 | 6691 | 6675 | 29561131 |
Minimal residual disease | 53.61 | 22.00 | 13 | 6708 | 330 | 29567476 |
Bacteraemia | 51.89 | 22.00 | 37 | 6684 | 16286 | 29551520 |
Ameloblastoma | 51.52 | 22.00 | 10 | 6711 | 84 | 29567722 |
Aspiration bone marrow abnormal | 49.50 | 22.00 | 10 | 6711 | 105 | 29567701 |
Leukaemia recurrent | 46.18 | 22.00 | 16 | 6705 | 1461 | 29566345 |
Multiple organ dysfunction syndrome | 44.75 | 22.00 | 63 | 6658 | 63053 | 29504753 |
Hypertensive hydrocephalus | 41.56 | 22.00 | 8 | 6713 | 64 | 29567742 |
Acute lymphocytic leukaemia recurrent | 41.26 | 22.00 | 17 | 6704 | 2499 | 29565307 |
Neoplasm progression | 39.09 | 22.00 | 33 | 6688 | 18579 | 29549227 |
Haematopoietic neoplasm | 37.19 | 22.00 | 7 | 6714 | 49 | 29567757 |
Thrombocytopenia | 36.80 | 22.00 | 89 | 6632 | 134734 | 29433072 |
Mucosal inflammation | 35.96 | 22.00 | 40 | 6681 | 31555 | 29536251 |
Abscess fungal | 35.19 | 22.00 | 8 | 6713 | 152 | 29567654 |
Neoplasm recurrence | 34.61 | 22.00 | 14 | 6707 | 1963 | 29565843 |
Cytogenetic abnormality | 34.07 | 22.00 | 11 | 6710 | 808 | 29566998 |
Clostridium bacteraemia | 33.87 | 22.00 | 7 | 6714 | 83 | 29567723 |
Aspergillus infection | 33.66 | 22.00 | 24 | 6697 | 10557 | 29557249 |
Cystitis haemorrhagic | 33.43 | 22.00 | 18 | 6703 | 4824 | 29562982 |
Pancytopenia | 33.11 | 22.00 | 64 | 6657 | 83104 | 29484702 |
Pneumonia fungal | 33.11 | 22.00 | 19 | 6702 | 5758 | 29562048 |
Cardiotoxicity | 30.98 | 22.00 | 17 | 6704 | 4727 | 29563079 |
Gallbladder adenocarcinoma | 30.02 | 22.00 | 5 | 6716 | 15 | 29567791 |
Product use in unapproved indication | 29.98 | 22.00 | 63 | 6658 | 86812 | 29480994 |
Venoocclusive liver disease | 29.95 | 22.00 | 19 | 6702 | 6898 | 29560908 |
Sepsis | 29.55 | 22.00 | 85 | 6636 | 142597 | 29425209 |
Neutropenic colitis | 28.73 | 22.00 | 13 | 6708 | 2398 | 29565408 |
Refractory anaemia with an excess of blasts | 27.97 | 22.00 | 8 | 6713 | 389 | 29567417 |
Disease progression | 27.80 | 22.00 | 59 | 6662 | 81857 | 29485949 |
Respiratory tract infection fungal | 27.73 | 22.00 | 9 | 6712 | 672 | 29567134 |
Klebsiella infection | 26.49 | 22.00 | 18 | 6703 | 7331 | 29560475 |
Genotoxicity | 26.44 | 22.00 | 5 | 6716 | 36 | 29567770 |
Klebsiella sepsis | 26.33 | 22.00 | 11 | 6710 | 1673 | 29566133 |
Enamel anomaly | 26.15 | 22.00 | 6 | 6715 | 119 | 29567687 |
Progressive multifocal leukoencephalopathy | 25.96 | 22.00 | 19 | 6702 | 8700 | 29559106 |
Colitis | 24.85 | 22.00 | 33 | 6688 | 31215 | 29536591 |
Hyperammonaemic encephalopathy | 24.57 | 22.00 | 11 | 6710 | 1979 | 29565827 |
Osteonecrosis | 24.41 | 22.00 | 22 | 6699 | 13497 | 29554309 |
Fungaemia | 23.60 | 22.00 | 11 | 6710 | 2170 | 29565636 |
Differentiation syndrome | 23.41 | 22.00 | 9 | 6712 | 1104 | 29566702 |
Large granular lymphocytosis | 23.41 | 22.00 | 6 | 6715 | 192 | 29567614 |
Cholangitis infective | 22.24 | 22.00 | 6 | 6715 | 235 | 29567571 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 537.19 | 20.30 | 351 | 10287 | 187306 | 64300788 |
Acute myeloid leukaemia | 328.61 | 20.30 | 135 | 10503 | 27328 | 64460766 |
Myelodysplastic syndrome | 314.51 | 20.30 | 131 | 10507 | 27448 | 64460646 |
Neutropenia | 179.97 | 20.30 | 209 | 10429 | 239415 | 64248679 |
Second primary malignancy | 169.35 | 20.30 | 67 | 10571 | 12270 | 64475824 |
Bone marrow failure | 149.43 | 20.30 | 95 | 10543 | 47857 | 64440237 |
Leukaemia recurrent | 115.24 | 20.30 | 34 | 10604 | 2560 | 64485534 |
Sepsis | 114.60 | 20.30 | 164 | 10474 | 230177 | 64257917 |
Bronchopulmonary aspergillosis | 102.75 | 20.30 | 54 | 10584 | 19031 | 64469063 |
Septic shock | 101.55 | 20.30 | 105 | 10533 | 105332 | 64382762 |
Thrombocytopenia | 99.25 | 20.30 | 151 | 10487 | 223650 | 64264444 |
Pancytopenia | 97.41 | 20.30 | 119 | 10519 | 143190 | 64344904 |
Acute promyelocytic leukaemia | 92.59 | 20.30 | 25 | 10613 | 1363 | 64486731 |
Mucormycosis | 87.39 | 20.30 | 36 | 10602 | 7305 | 64480789 |
Progressive multifocal leukoencephalopathy | 77.15 | 20.30 | 44 | 10594 | 18188 | 64469906 |
Acute lymphocytic leukaemia recurrent | 73.74 | 20.30 | 27 | 10611 | 3999 | 64484095 |
Fungal infection | 71.41 | 20.30 | 53 | 10585 | 34198 | 64453896 |
Product use in unapproved indication | 69.65 | 20.30 | 113 | 10525 | 176505 | 64311589 |
Multiple organ dysfunction syndrome | 68.50 | 20.30 | 84 | 10554 | 101329 | 64386765 |
Bacteraemia | 68.44 | 20.30 | 47 | 10591 | 26864 | 64461230 |
Acute myeloid leukaemia recurrent | 63.61 | 20.30 | 22 | 10616 | 2762 | 64485332 |
Venoocclusive liver disease | 61.59 | 20.30 | 31 | 10607 | 9984 | 64478110 |
Clostridium bacteraemia | 59.92 | 20.30 | 13 | 10625 | 277 | 64487817 |
Haemophagocytic lymphohistiocytosis | 55.07 | 20.30 | 35 | 10603 | 17574 | 64470520 |
Aspergillus infection | 54.86 | 20.30 | 34 | 10604 | 16345 | 64471749 |
Ameloblastoma | 54.71 | 20.30 | 10 | 10628 | 84 | 64488010 |
Neoplasm recurrence | 53.72 | 20.30 | 21 | 10617 | 3718 | 64484376 |
Cytogenetic abnormality | 52.05 | 20.30 | 15 | 10623 | 1039 | 64487055 |
Refractory anaemia with an excess of blasts | 50.67 | 20.30 | 14 | 10624 | 832 | 64487262 |
Lower respiratory tract infection fungal | 50.52 | 20.30 | 14 | 10624 | 841 | 64487253 |
Chronic hepatitis | 49.31 | 20.30 | 15 | 10623 | 1253 | 64486841 |
Febrile bone marrow aplasia | 47.17 | 20.30 | 27 | 10611 | 11228 | 64476866 |
Neoplasm progression | 47.15 | 20.30 | 45 | 10593 | 40919 | 64447175 |
Differentiation syndrome | 46.03 | 20.30 | 16 | 10622 | 2038 | 64486056 |
Fungaemia | 43.15 | 20.30 | 18 | 10620 | 3767 | 64484327 |
Respiratory failure | 42.90 | 20.30 | 87 | 10551 | 161096 | 64326998 |
Klebsiella sepsis | 42.16 | 20.30 | 16 | 10622 | 2616 | 64485478 |
Drug resistance | 41.24 | 20.30 | 39 | 10599 | 35063 | 64453031 |
Stenotrophomonas infection | 39.72 | 20.30 | 16 | 10622 | 3064 | 64485030 |
Colitis | 38.62 | 20.30 | 48 | 10590 | 58626 | 64429468 |
Stem cell transplant | 37.83 | 20.30 | 16 | 10622 | 3465 | 64484629 |
Aplastic anaemia | 37.01 | 20.30 | 25 | 10613 | 13895 | 64474199 |
Neutropenic colitis | 36.70 | 20.30 | 17 | 10621 | 4564 | 64483530 |
Fatigue | 36.51 | 20.30 | 42 | 10596 | 748688 | 63739406 |
Haematotoxicity | 36.31 | 20.30 | 24 | 10614 | 12872 | 64475222 |
Abdominal wall wound | 36.11 | 20.30 | 7 | 10631 | 83 | 64488011 |
Cystitis haemorrhagic | 35.81 | 20.30 | 20 | 10618 | 7936 | 64480158 |
Haematopoietic neoplasm | 35.81 | 20.30 | 7 | 10631 | 87 | 64488007 |
Hyperammonaemic encephalopathy | 35.47 | 20.30 | 16 | 10622 | 4042 | 64484052 |
Candida infection | 35.18 | 20.30 | 34 | 10604 | 31385 | 64456709 |
Malignant neoplasm progression | 34.99 | 20.30 | 65 | 10573 | 112806 | 64375288 |
Graft versus host disease | 34.81 | 20.30 | 24 | 10614 | 13789 | 64474305 |
Respiratory tract infection fungal | 34.42 | 20.30 | 11 | 10627 | 1081 | 64487013 |
Stomatococcal infection | 34.16 | 20.30 | 8 | 10630 | 243 | 64487851 |
Myeloblast percentage decreased | 33.92 | 20.30 | 6 | 10632 | 41 | 64488053 |
Refractory cytopenia with multilineage dysplasia | 33.55 | 20.30 | 8 | 10630 | 263 | 64487831 |
Hypogammaglobulinaemia | 33.53 | 20.30 | 21 | 10617 | 10278 | 64477816 |
Cardiomyopathy | 33.33 | 20.30 | 30 | 10608 | 25326 | 64462768 |
Bone marrow infiltration | 33.28 | 20.30 | 9 | 10629 | 493 | 64487601 |
Hypertensive hydrocephalus | 33.06 | 20.30 | 5 | 10633 | 10 | 64488084 |
Enterococcal infection | 32.40 | 20.30 | 23 | 10615 | 13843 | 64474251 |
Cardiac failure | 32.34 | 20.30 | 69 | 10569 | 132304 | 64355790 |
Pyrexia | 31.70 | 20.30 | 178 | 10460 | 558466 | 63929628 |
Mucosal inflammation | 31.64 | 20.30 | 45 | 10593 | 62539 | 64425555 |
Nausea | 31.33 | 20.30 | 51 | 10587 | 785749 | 63702345 |
Arthralgia | 31.33 | 20.30 | 17 | 10621 | 442243 | 64045851 |
Acute lymphocytic leukaemia | 31.26 | 20.30 | 15 | 10623 | 4356 | 64483738 |
Hepatic failure | 31.25 | 20.30 | 42 | 10596 | 55352 | 64432742 |
Diffuse large B-cell lymphoma recurrent | 29.40 | 20.30 | 13 | 10625 | 3133 | 64484961 |
Pain | 29.22 | 20.30 | 29 | 10609 | 553482 | 63934612 |
Abscess fungal | 28.85 | 20.30 | 7 | 10631 | 248 | 64487846 |
Osteonecrosis | 28.73 | 20.30 | 29 | 10609 | 28200 | 64459894 |
Acute febrile neutrophilic dermatosis | 28.70 | 20.30 | 13 | 10625 | 3316 | 64484778 |
Pneumonia fungal | 28.64 | 20.30 | 18 | 10620 | 8859 | 64479235 |
Drug hypersensitivity | 28.57 | 20.30 | 3 | 10635 | 237812 | 64250282 |
Chronic myeloid leukaemia | 28.53 | 20.30 | 13 | 10625 | 3361 | 64484733 |
Hepatitis B | 28.29 | 20.30 | 17 | 10621 | 7728 | 64480366 |
Fall | 28.12 | 20.30 | 17 | 10621 | 416809 | 64071285 |
Chronic lymphocytic leukaemia recurrent | 27.70 | 20.30 | 8 | 10630 | 558 | 64487536 |
Lymphopenia | 27.29 | 20.30 | 27 | 10611 | 25630 | 64462464 |
Pseudomonas infection | 27.21 | 20.30 | 23 | 10615 | 17860 | 64470234 |
Disseminated intravascular coagulation | 27.17 | 20.30 | 30 | 10608 | 32318 | 64455776 |
Aspiration bone marrow abnormal | 27.09 | 20.30 | 6 | 10632 | 141 | 64487953 |
Disease progression | 27.03 | 20.30 | 67 | 10571 | 141613 | 64346481 |
Pruritus | 26.91 | 20.30 | 9 | 10629 | 312391 | 64175703 |
Pulmonary haemorrhage | 26.67 | 20.30 | 20 | 10618 | 13089 | 64475005 |
Klebsiella infection | 26.44 | 20.30 | 20 | 10618 | 13261 | 64474833 |
Cardiotoxicity | 26.24 | 20.30 | 18 | 10620 | 10256 | 64477838 |
Leukopenia | 26.14 | 20.30 | 54 | 10584 | 101188 | 64386906 |
Chloroma | 25.97 | 20.30 | 8 | 10630 | 697 | 64487397 |
Hepatitis E | 25.84 | 20.30 | 11 | 10627 | 2420 | 64485674 |
Dizziness | 25.75 | 20.30 | 20 | 10618 | 430143 | 64057951 |
Blood culture positive | 25.50 | 20.30 | 16 | 10622 | 7852 | 64480242 |
Escherichia bacteraemia | 25.46 | 20.30 | 14 | 10624 | 5389 | 64482705 |
Minimal residual disease | 25.43 | 20.30 | 7 | 10631 | 410 | 64487684 |
Staphylococcal infection | 24.96 | 20.30 | 36 | 10602 | 50642 | 64437452 |
Chromosome analysis abnormal | 24.58 | 20.30 | 6 | 10632 | 218 | 64487876 |
Pain in extremity | 23.97 | 20.30 | 10 | 10628 | 303075 | 64185019 |
Portal hypertension | 23.63 | 20.30 | 14 | 10624 | 6205 | 64481889 |
Streptococcal bacteraemia | 23.39 | 20.30 | 11 | 10627 | 3056 | 64485038 |
Pseudomonal sepsis | 23.27 | 20.30 | 13 | 10625 | 5159 | 64482935 |
Acute myelomonocytic leukaemia | 23.04 | 20.30 | 6 | 10632 | 284 | 64487810 |
Streptococcal sepsis | 22.73 | 20.30 | 10 | 10628 | 2382 | 64485712 |
Encephalopathy | 22.27 | 20.30 | 37 | 10601 | 58782 | 64429312 |
Nasopharyngitis | 22.25 | 20.30 | 3 | 10635 | 196070 | 64292024 |
Cerebral fungal infection | 22.11 | 20.30 | 6 | 10632 | 333 | 64487761 |
Metastasis | 22.11 | 20.30 | 13 | 10625 | 5682 | 64482412 |
Large granular lymphocytosis | 21.94 | 20.30 | 6 | 10632 | 343 | 64487751 |
Leukaemic infiltration | 21.70 | 20.30 | 5 | 10633 | 141 | 64487953 |
Chronic myelomonocytic leukaemia | 21.33 | 20.30 | 7 | 10631 | 748 | 64487346 |
Bacterial sepsis | 21.29 | 20.30 | 14 | 10624 | 7443 | 64480651 |
Pneumonia | 21.10 | 20.30 | 161 | 10477 | 559415 | 63928679 |
Acute graft versus host disease | 21.06 | 20.30 | 15 | 10623 | 9069 | 64479025 |
Primary hypogonadism | 20.75 | 20.30 | 5 | 10633 | 172 | 64487922 |
Parametritis | 20.59 | 20.30 | 3 | 10635 | 4 | 64488090 |
Retinal infiltrates | 20.51 | 20.30 | 4 | 10634 | 49 | 64488045 |
Cholangitis infective | 20.31 | 20.30 | 6 | 10632 | 453 | 64487641 |
None
Source | Code | Description |
---|---|---|
ATC | L01DB07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
FDA MoA | N0000000176 | Topoisomerase Inhibitors |
MeSH PA | D000700 | Analgesics |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
MeSH PA | D059005 | Topoisomerase II Inhibitors |
FDA EPC | N0000175609 | Topoisomerase Inhibitor |
CHEBI has role | CHEBI:23240 | chromophores |
CHEBI has role | CHEBI:37958 | dyes |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute myeloid leukemia, disease | indication | 91861009 | |
Relapsing remitting multiple sclerosis | indication | 426373005 | DOID:2378 |
Metastatic Prostate Carcinoma | indication | ||
Follicular non-Hodgkin's lymphoma | off-label use | 308121000 | |
Metastatic Breast Carcinoma | off-label use | ||
Progressive Diffuse Large B-Cell Lymphoma | off-label use | ||
Mycosis | contraindication | 3218000 | DOID:1564 |
Viral disease | contraindication | 34014006 | DOID:934 |
Chronic heart failure | contraindication | 48447003 | |
Hepatic failure | contraindication | 59927004 | |
Acute infectious disease | contraindication | 63171007 | |
Leukopenia | contraindication | 84828003 | DOID:615 |
Left heart failure | contraindication | 85232009 | |
Bacterial infectious disease | contraindication | 87628006 | |
Radiation oncology AND/OR radiotherapy | contraindication | 108290001 | |
Acute disease of cardiovascular system | contraindication | 128487001 | |
Seizure disorder | contraindication | 128613002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.37 | acidic |
pKa2 | 10.7 | acidic |
pKa3 | 9.13 | Basic |
pKa4 | 8.52 | Basic |
pKa5 | 4.01 | Basic |
pKa6 | 1.49 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA topoisomerase 2-alpha | Enzyme | INHIBITOR | IC90 | 5.96 | WOMBAT-PK | CHEMBL | |||
Multidrug resistance protein 1 | Transporter | IC50 | 5.84 | WOMBAT-PK | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.31 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.73 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.74 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.11 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.05 | DRUG MATRIX | |||||
Canalicular multispecific organic anion transporter 1 | Transporter | WOMBAT-PK | |||||||
Multidrug resistance-associated protein 1 | Transporter | IC50 | 6.29 | WOMBAT-PK | |||||
ATP-binding cassette sub-family G member 2 | Transporter | Kact | 5.16 | WOMBAT-PK | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.27 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.90 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.69 | DRUG MATRIX | |||||
Serine/threonine-protein kinase pim-1 | Kinase | IC50 | 7.29 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.36 | CHEMBL | |||||
DNA-(apurinic or apyrimidinic site) lyase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
Tyrosine-protein kinase BTK | Kinase | IC50 | 6 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase ROS | Kinase | IC50 | 5.52 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 4.13 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 6.72 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 6.28 | CHEMBL | |||||
Solute carrier family 22 member 3 | Transporter | IC50 | 4.22 | CHEMBL | |||||
DNA-3-methyladenine glycosylase | Enzyme | IC50 | 5.60 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 5.53 | DRUG MATRIX | |||||
TAR DNA-binding protein 43 | Unclassified | IC50 | 5 | CHEMBL | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.75 | DRUG MATRIX | |||||
Integrase | Enzyme | IC50 | 5.42 | CHEMBL | |||||
Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Kinase | AC50 | 5.02 | CHEMBL |
ID | Source |
---|---|
4019842 | VUID |
N0000147929 | NUI |
D02166 | KEGG_DRUG |
70476-82-3 | SECONDARY_CAS_RN |
4019527 | VANDF |
4019842 | VANDF |
C0026259 | UMLSCUI |
CHEBI:50729 | CHEBI |
MIX | PDB_CHEM_ID |
CHEMBL58 | ChEMBL_ID |
CHEMBL1417019 | ChEMBL_ID |
CHEMBL1200827 | ChEMBL_ID |
D008942 | MESH_DESCRIPTOR_UI |
DB01204 | DRUGBANK_ID |
7242 | IUPHAR_LIGAND_ID |
4922 | INN_ID |
BZ114NVM5P | UNII |
4212 | PUBCHEM_CID |
203129 | RXNORM |
5124 | MMSL |
81184 | MMSL |
d00306 | MMSL |
002676 | NDDF |
004828 | NDDF |
108791001 | SNOMEDCT_US |
386913001 | SNOMEDCT_US |
412249002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4680 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4685 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4686 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-343 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 28 sections |
Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-343 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 28 sections |
Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-132 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 15 sections |